Loading clinical trials...
Loading clinical trials...
The hypothesis of this study is that SER120 is safe and well tolerated for use in nocturic patients.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Serenity Pharmaceuticals, Inc.
NCT05562388 · Obstructive Sleep Apnea, Nocturia, and more
NCT05300308 · Urogenital Cancer, Lower Limb Lymphedema, and more
NCT06866834 · Women, Urinary Incontinence (UI), and more
NCT05222477 · Nocturia, Sleep Deprivation
NCT03883724 · Sleep Fragmentation, Poor Quality Sleep, and more
Stephen M. Auerbach, MD
Newport Beach, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions